Clinical genomics, read and reviewed for you
Every week, the most relevant publications in constitutional genetics, hereditary cancer, pharmacogenomics and bioinformatics — curated, scored against a public grid and reviewed by a medical biologist. Free, ad-free.
Every week, ~1,100 publications are screened down to a curated, scored selection — over ~26,700 publications examined since launch.
This week on Geno'X
Four domains, one report per week each.
Clopidogrel is first-line for secondary stroke prevention, but its effectiveness depends on CYP2C19 genotype. This prospective observational quality-improvement cohort deployed rapid CYP2C19 testing across three comprehensive stroke centers of one health system between September 2024 and August 2025. Results were available for 467 patients, 451 (97%) before discharge, with a median turnaround of 5.2 hours. Among 296 patients with stroke or TIA discharged on a P2Y12 inhibitor, ticagrelor was prescribed in 87% of intermediate/poor metabolizers (89/102) versus 5.7% of the others (11/194; RR 15.4; 95% CI 8.6-27.4; P < 0.0001). Prescribing matched genotype-based recommendations in 92% of patients.
The watch in numbers
Selection funnel, score distribution, most-covered genes — the full curation mechanics, in the open.
Explore the watch in numbersHow it works
1. Exhaustive collection
Every week, PubMed, around a hundred specialty journals and bioRxiv/medRxiv preprints are screened across all 4 domains.
2. Transparent scoring
Each article is scored out of 10 against a public 5-criteria grid — clinical impact first. The score breakdown is shown on every article page.
3. Signed expert analysis
Every selected article is read and reviewed by a medical biologist: bilingual FR/EN summary and critical perspective — no black-box generated digest.
The full scoring grid is public: see the methodology.
Who is behind Geno'X?
Geno'X Veille is published by Dr Thibaut Benquey, a medical biologist specializing in constitutional genomics (WGS/WES) — from rare disease diagnosis to the clinical applications of next-generation sequencing. Every article is personally curated, scored and reviewed: no mass-generated content, no black box.
Follow on LinkedInWhy it's free
Geno'X Veille is a personal project — no ads, no sponsors, no sponsored content. No data is ever sold. The goal isn't commercial: it's to make clinical-genomics literature monitoring accessible to the whole community — biologists, geneticists, residents, genetic counsellors.
If you find the project useful, you can support hosting and curation time via Ko-fi — entirely optional.
Support on Ko-fiEvery Wednesday · Annotated selection · Free · Unsubscribe anytime